VANCOUVER, BC, May 25, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy (“MDMA-AT”) in…

Source

Previous articlePT411 – The Humanity of Healthcare Professionals, Ancient Psychedelic Use, and Breaking the Cycle of Colonialism
Next articleData Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023